Aurigene pharmaceutical services offers Murine CT26 colon carcinoma tumor model used for evaluating the NCE’s or drug combinations immune checkpoint inhibitors. Our animal model is validated and tends to show objective response rates to a number of commercially available checkpoint inhibitors.
CT26 validation with anti-PD1 Antibody and Chemotherapy 5-Floro uracil Treatment.
CT26 cell line will be grown in medium supplemented with 10% FBS, and cultured at 37±1 °C in an incubator supplied with 5% carbon dioxide. BALB/c Mice are implanted at right flank area at desired cell density injected into subcutaneous region. Mice are randomized after reaching desired tumor volume cohort size and are subjected to treatment. End points like Tumor Growth Delay, Tumor Growth Inhibition (TGI), Tumor weight, Body weight changes, PK and PD parameters and tumor immunohistochemistry are assessed. Rechallenge of Mice are done for cured mice with age match control.
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.